Tag Archives: European Medicines Agency

February, 2016

• 26 February

  AbbVie Announces Positive CHMP Opinion for Viekirax without Ribavirin in HCV

  

  NORTH CHICAGO, Ill., Feb. 26, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without …

  Share

  • Facebook
  • Twitter
  • LinkedIn

October, 2015

• 19 October

  Clinical Perspectives of Biosimilars in Rheumatology

  

  Drugs produced using biotechnology are among the most expensive medicines available. Biosimilars that offer a real alternative are becoming increasingly available on the market. The promise of biosimilars is that, once patent protection has elapsed for established biologics, more patients will be able to access effective and well-tolerated drugs. This …

  Share

  • Facebook
  • Twitter
  • LinkedIn